AgomAb Therapeutics NV
AGMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002020932
In the last 90 days, AgomAb Therapeutics NV insiders filed 7 open-market purchases and 0 sales; 34 institutions reported holding it in 13F filings for Q2 2026, worth $337.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by AgomAb Therapeutics NV insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 7 filings
- 3 insiders, $592.1K in total
- Open-market sells
- 0 filings
- Insiders trading
- 3
- Net value
- +$592.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for AgomAb Therapeutics NV, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Epstein David R | Director | 54,980 | Nov 16, 2026 | 5 |
| Kemula Pierre Thadee Victor | Chief Financial Officer | 10,000 | Oct 7, 2026 | 1 |
| Knotnerus Tim Jasper | Chief Executive Officer | 21,823 | Oct 7, 2026 | 1 |
| Garcia Marino | Director | – | Sep 15, 2026 | 1 |
| Patel Naimish | Director | – | Sep 15, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 (view filing)6:43 AM ET | Nov 13 | 3 days | Epstein David RDirector | PPurchase | +15.0K | $5.92 | +$88.7K | +37.5%55.0K after | 4 lots |
| Nov 6, 2026 (view filing)6:39 AM ET | Nov 5 | 1 day | Epstein David RDirector | PPurchase | +15.0K | $6.90 | +$103.5K | +60.0%40.0K after | 3 lots |
| Oct 22, 2026 (view filing)8:14 AM ET | Oct 21 | 1 day | Epstein David RDirector | PPurchase | +10.0K | $8.88 | +$88.8K | +66.7%25.0K after | 2 lots |
| Oct 9, 2026 (view filing)8:01 AM ET | Oct 8 | 1 day | Epstein David RDirector | PPurchase | +5.00K | $8.90 | +$44.5K | +50.0%15.0K after | |
| Oct 7, 2026 (view filing)8:57 AM ET | Oct 5-6 | 2 days | Epstein David RDirector | PPurchase | +10.0K | $8.64 | +$86.3K | New position10.0K after | 2 lots |
| Oct 7, 2026 (view filing)8:47 AM ET | Oct 6 | 1 day | Kemula Pierre Thadee VictorChief Financial Officer | PPurchase | +10.0K | $8.59 | +$85.9K | New position10.0K after | 3 lots |
| Oct 7, 2026 (view filing)8:06 AM ET | Oct 5-6 | 2 days | Knotnerus Tim JasperChief Executive Officer | PPurchase | +11.0K | $8.58 | +$94.4K | +101.6%21.8K after | 2 lots |